Skip to content
Subscriber Only

Drugmaker Chiefs May Be FDA Targets for Off-Label Use

Drugmaker executives whose companies promote unauthorized uses of their medicines may be targeted by U.S. regulators for misdemeanor prosecutions, Food and Drug Administration Deputy Chief for Litigation Eric Blumberg said.

Blumberg didn’t offer a timetable for the agency to take such actions during remarks yesterday at Washington conference. He cited Pfizer Inc., the world’s largest drugmaker, for violations of a federal law that bars manufacturers from promoting drugs for uses other than those approved by the agency, a practice called off-label marketing.